Drug Profile
Research programme: HIV and AIDS therapeutics - SRI International
Latest Information Update: 25 Apr 2023
Price :
$50
*
At a glance
- Originator SRI International
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for HIV infections in USA (unspecified route)
- 28 Aug 2018 No recent reports of development identified for preclinical development in HIV-infections in USA
- 24 Jul 2014 Preclinical trials in HIV infections in USA (unspecified route)